HKD78.45
4.67% today
Hong Kong, Jun 12, 10:08 am CET
ISIN
CNE1000031K4
Symbol
2359
Index
Sector
Industry

WuXi AppTec Stock price

HKD74.95
+12.52 20.05% 1M
+17.34 30.09% 6M
+18.78 33.43% YTD
+41.99 127.42% 1Y
+1.51 2.05% 5Y
+46.21 160.76% 10Y
+46.21 160.76% 20Y
Hong Kong, Closing price Wed, Jun 11 2025
+0.95 1.28%
ISIN
CNE1000031K4
Symbol
2359
Index
Sector
Industry

Key metrics

Market capitalization HKD201.08b
P/E (TTM) P/E ratio 17.55
P/S ratio (TTM) P/S ratio 4.50
Dividend yield 1.41%
Last dividend (FY24) HKD1.43
Revenue growth (TTM) Revenue growth 3.95%
Revenue (TTM) Revenue HKD44.64b
EBIT (operating result TTM) EBIT HKD11.94b
Free Cash Flow (TTM) Free Cash Flow HKD10.28b
EPS (TTM) EPS HKD4.27
P/E forward 17.19
P/S forward 4.39
Show more

Is WuXi AppTec a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

WuXi AppTec Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a WuXi AppTec forecast:

17x Buy
81%
3x Hold
14%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a WuXi AppTec forecast:

Buy
81%
Hold
14%
Sell
5%

Financial data from WuXi AppTec

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
44,642 44,642
4% 4%
100%
- Direct Costs 26,097 26,097
1% 1%
58%
18,545 18,545
8% 8%
42%
- Selling and Administrative Expenses 4,389 4,389
7% 7%
10%
- Research and Development Expense 1,262 1,262
17% 17%
3%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 11,942 11,942
0% 0%
27%
Net Profit 12,179 12,179
19% 19%
27%

In millions HKD.

Don't miss a Thing! We will send you all news about WuXi AppTec directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China.

Head office China
CEO Min Chen
Employees 39,414
Founded 2000
Website www.wuxiapptec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today